Innovation in the pharmaceutical industry: New estimates of R&D costs
Innovation in the pharmaceutical industry: New estimates of R&D costs
复制标题
DOI：
10.1016/j.jhealeco.2016.01.012
复制
发表时间：
2016-05-01
影响因子：
3.5
通讯作者：
Hansen, Ronald W.
中科院分区：
文献类型：
--
作者：
DiMasi, Joseph A.;Grabowski, Henry G.;Hansen, Ronald W.
通过对10家制药公司的调查，获得了随机抽取的106种新药的研发成本。这些数据用于估计新药和生物制剂开发的平均税前成本。测试期间废弃的化合物的成本与获得上市批准的化合物的成本相关。每个批准的新化合物的平均自付费用估计为 13.95 亿美元（2013 年美元）。以 10.5% 的实际贴现率将自付费用资本化至上市批准时，预批准成本估算总额为 25.58 亿美元（2013 年美元）。与本系列之前的研究结果相比，总资本成本以年增长率 8.5% 的速度增长，高于总体价格通胀。加上批准后研发成本的估算，成本估算增加至 28.7 亿美元（2013 年美元）。 (C) 2016 Elsevier B.V. 保留所有权利。
The research and development costs of 106 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug and biologics development. The costs of compounds abandoned during testing were linked to the costs of compounds that obtained marketing approval. The estimated average out-of-pocket cost per approved new compound is $1395 million (2013 dollars). Capitalizing out-of-pocket costs to the point of marketing approval at a real discount rate of 10.5% yields a total pre-approval cost estimate of $2558 million (2013 dollars). When compared to the results of the previous study in this series, total capitalized costs were shown to have increased at an annual rate of 8.5% above general price inflation. Adding an estimate of post-approval R&D costs increases the cost estimate to $2870 million (2013 dollars). (C) 2016 Elsevier B.V. All rights reserved.